Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging.

Guérin B, Dumulon-Perreault V, Tremblay MC, Ait-Mohand S, Fournier P, Dubuc C, Authier S, Bénard F.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):950-3. doi: 10.1016/j.bmcl.2009.12.068. Epub 2009 Dec 23.

PMID:
20042335
2.

Novel chemically modified analogues of neuropeptide Y for tumor targeting.

Zwanziger D, Khan IU, Neundorf I, Sieger S, Lehmann L, Friebe M, Dinkelborg L, Beck-Sickinger AG.

Bioconjug Chem. 2008 Jul;19(7):1430-8. doi: 10.1021/bc7004297. Epub 2008 Jun 24.

PMID:
18572959
3.

Ligand binding and functional effects of systematic double D-amino acid residue substituted neuropeptide Y analogs on Y1 and Y2 receptor types.

Grundemar L, Kahl U, Callréus T, Langel U, Bienert M, Beyermann M.

Regul Pept. 1996 Apr 23;62(2-3):131-6.

PMID:
8795076
4.

Modeling of neuropeptide receptors Y1, Y4, Y5, and docking studies with neuropeptide antagonist.

Jois SD, Nagarajarao LM, Prabhakaran M, Balasubramaniam A.

J Biomol Struct Dyn. 2006 Apr;23(5):497-508.

PMID:
16494499
5.

Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line.

Sheriff S, Ali M, Yahya A, Haider KH, Balasubramaniam A, Amlal H.

Mol Cancer Res. 2010 Apr;8(4):604-14. doi: 10.1158/1541-7786.MCR-09-0301. Epub 2010 Mar 23.

6.

Pharmacological characterization of (125)I-1229U91 binding to Y1 and Y4 neuropeptide Y/Peptide YY receptors.

Schober DA, Gackenheimer SL, Heiman ML, Gehlert DR.

J Pharmacol Exp Ther. 2000 Apr;293(1):275-80.

7.

[Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist.

Fuhlendorff J, Gether U, Aakerlund L, Langeland-Johansen N, Thøgersen H, Melberg SG, Olsen UB, Thastrup O, Schwartz TW.

Proc Natl Acad Sci U S A. 1990 Jan;87(1):182-6.

8.

Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.

Kirby DA, Boublik JH, Rivier JE.

J Med Chem. 1993 Nov 26;36(24):3802-8.

PMID:
8254609
9.

Novel analogues of neuropeptide Y with a preference for the Y1-receptor.

Söll RM, Dinger MC, Lundell I, Larhammer D, Beck-Sickinger AG.

Eur J Biochem. 2001 May;268(10):2828-37.

10.

Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells.

Shrivastava A, Wang SH, Raju N, Gierach I, Ding H, Tweedle MF.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):687-92. doi: 10.1016/j.bmcl.2012.11.110. Epub 2012 Dec 5.

11.

Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors.

Grandt D, Schimiczek M, Rascher W, Feth F, Shively J, Lee TD, Davis MT, Reeve JR Jr, Michel MC.

Regul Pept. 1996 Nov 14;67(1):33-7.

PMID:
8952003
12.
13.
14.

Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.

Kirby DA, Koerber SC, Craig AG, Feinstein RD, Delmas L, Brown MR, Rivier JE.

J Med Chem. 1993 Feb 5;36(3):385-93.

PMID:
8426366
15.

First selective agonist of the neuropeptide Y1-receptor with reduced size.

Zwanziger D, Böhme I, Lindner D, Beck-Sickinger AG.

J Pept Sci. 2009 Dec;15(12):856-66. doi: 10.1002/psc.1188.

PMID:
19890892
16.

Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass.

Kirby DA, Koerber SC, May JM, Hagaman C, Cullen MJ, Pelleymounter MA, Rivier JE.

J Med Chem. 1995 Oct 27;38(22):4579-86.

PMID:
7473586
17.

Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.

Wieland HA, Willim KD, Entzeroth M, Wienen W, Rudolf K, Eberlein W, Engel W, Doods HN.

J Pharmacol Exp Ther. 1995 Oct;275(1):143-9.

PMID:
7562543
18.

A Y2 receptor mimetic aptamer directed against neuropeptide Y.

Proske D, Höfliger M, Söll RM, Beck-Sickinger AG, Famulok M.

J Biol Chem. 2002 Mar 29;277(13):11416-22. Epub 2001 Dec 27.

19.

Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.

Berglund MM, Saar K, Lundell I, Langel U, Larhammar D.

Neuropeptides. 2001 Jun-Aug;35(3-4):148-53.

PMID:
11884204
20.

Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.

Koumarianou E, Mikołajczak R, Pawlak D, Zikos X, Bouziotis P, Garnuszek P, Karczmarczyk U, Maurin M, Archimandritis SC.

Nucl Med Biol. 2009 Aug;36(6):591-603. doi: 10.1016/j.nucmedbio.2009.03.006.

PMID:
19647165
Items per page

Supplemental Content

Write to the Help Desk